Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Badri Modi

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Journal of Investigative Dermatology|February 20, 2021
Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation SurvivorsJennifer Berano Teh, Farah Abdulla, Kelly Peng, et al.
Bone Marrow Transplantation|April 20, 2022
Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host diseaseAmandeep Salhotra, Min Talley, Xiwei Wu, et al.
BMC Cancer|August 5, 2020
Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH)Saro H Armenian, Lanie Lindenfeld, Aleksi Iukuridze, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2018
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host DiseaseBadri Modi, Michael Hernandez-Henderson, Dongyun Yang, et al.
Therapeutic Advances in Medical Oncology|November 29, 2023
CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case studyYuan Yuan, Colt Egelston, Oscar Colunga Flores, et al.
Transplantation and Cellular Therapy|January 15, 2026
Towards Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task ForceAlina Markova, Stephanie J Lee, Badri Modi, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
The New England Journal of Medicine|June 5, 2018
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Investigative Dermatology|February 20, 2021
Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation SurvivorsJennifer Berano Teh, Farah Abdulla, Kelly Peng, et al.
Bone Marrow Transplantation|April 20, 2022
Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host diseaseAmandeep Salhotra, Min Talley, Xiwei Wu, et al.
BMC Cancer|August 5, 2020
Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH)Saro H Armenian, Lanie Lindenfeld, Aleksi Iukuridze, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2018
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host DiseaseBadri Modi, Michael Hernandez-Henderson, Dongyun Yang, et al.
Therapeutic Advances in Medical Oncology|November 29, 2023
CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case studyYuan Yuan, Colt Egelston, Oscar Colunga Flores, et al.
Transplantation and Cellular Therapy|January 15, 2026
Towards Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task ForceAlina Markova, Stephanie J Lee, Badri Modi, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
The New England Journal of Medicine|June 5, 2018
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 3